advertisement
Abstract #127994 Published in IGR 25-3
Third-Generation Trabecular Micro-Bypass Implantation and Phacoemulsification in Patients with Glaucoma: A Multicenter Study
Shultz M; Vest ZM; Trubnik V; Sarkisian SR; Hornbeak DMVision (Basel, Switzerland) 2025; 9:
This multicenter study evaluated the effectiveness and safety of third-generation trabecular micro-bypass implantation (iStent infinite) combined with phacoemulsification (n = 233 eyes). Key outcomes through 12 months included the mean change in intraocular pressure (IOP) and the number of topical medications, as well as proportions achieving IOPs ≤ 18/15/12 mmHg or using 0/1/2/ ≥ 3 medications. In all eyes with 12-month follow-up data (n = 96, consistent cohort), the mean IOP reduced from 17.2 ± 4.2 mmHg preoperatively to 13.8 ± 3.0 mmHg at Month 12 ( = 0.001), while the mean number of medications reduced from 1.24 ± 0.91 preoperatively to 0.61 ± 0.96 at Month 12 ( = 0.001). The proportions of eyes achieving IOP ≤ 18/15/12 mmHg increased from 63.5%, 34.4%, and 14.6% preoperatively to 92.7%, 71.9%, and 37.5%, respectively at Month 12, (all = 0.001). The proportions of eyes off medication increased from 16.7% preoperatively to 62.5% at Month 12 ( = 0.001). This study provides clinically relevant, real-world results that demonstrate significant reductions in IOP and the number of topical glaucoma medications required following iStent infinite trabecular micro-bypass and phacoemulsification.
Shultz-Chang Vision, 18350 Roscoe Blvd #101, Northridge, CA 91325, USA.
Full article